Almac Group strengthens its position in the CDMO market

| By | Almac Group, CDMO, Laboratories
0
68

Almac Group, the global contract development and manufacturing organisation, announced its global analytical services capabilities spanning UK, Europe and USA.

Following the successful acquisition of BioClin Research Laboratories in 2017, Almac’s Sciences Business Unit has united its world-class capabilities to form an analytical group which can meet the varying demands required within its clients’ development programs. From 1st October, BioClin will rename under the Almac Sciences brand, further strengthening its offering and presenting a unified platform within the pharmaceutical industry.

Employing 150 highly skilled analysts working in GMP / GLP environments from its 3 locations in Craigavon (UK); Athlone (Ireland); and Souderton, Pennsylvania (USA), Almac is positioned as the partner of choice with significant experience in the analysis of both small and large molecules, and a range of product types including peptides, biologics, conjugates, potents and controlled substances.

In order to satisfy client demand, resource at Almac’s US Pennsylvania-based facility has also increased by 30%. The 232 sq m laboratory provides GMP analytical support to the pharmaceutical industry including analytical method development and validation, GMP stability studies and clinical and commercial product release.

The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery development and commercialisation, API manufacture, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

SOURCE: almac group
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.